The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells
The incidence of treatment-related neuroendocrine (NE) prostate cancer (t-NEPC) is rising as more potent drugs targeting the androgen signaling axis are clinically implemented. Neuroendocrine transdifferentiation (NEtD), an putative initial step in t-NEPC development, is induced by androgen deprivat...
Egile Nagusiak: | Braadland, PR, Ramberg, H, Grytli, HH, Urbanucci, A, Nielsen, HK, Guldvik, IJ, Engedal, A, Ketola, K, Wang, W, Svindland, A, Mills, IG, Bjartell, A, Tasken, KA |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
American Association of Cancer Research
2019
|
Antzeko izenburuak
-
β-Adrenergic receptor signaling in prostate cancer
nork: Peder Rustøen Braadland, et al.
Argitaratua: (2015-01-01) -
Low blood levels of LRG1 before radical prostatectomy identify patients with high risk of progression to castration-resistant prostate cancer
nork: Guldvik, IJ, et al.
Argitaratua: (2022) -
Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy
nork: Guldvik, IJ, et al.
Argitaratua: (2024) -
Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification
nork: Guldvik, IJ, et al.
Argitaratua: (2020) -
Non-selective beta-blocker use is associated with reduced cancer recurrence after radical prostatectomy: A prospective cohort study on 11256 radically operated patients
nork: S. Sivanesan, et al.
Argitaratua: (2020-07-01)